- Policy
- MOHW provides real-time confirmation service
- by Lee, Jeong-Hwan Mar 15, 2023 05:56am
- When the government requests pharmaceutical companies to expand drug reimbursement standards, the government plans to use the information system to provide administrative services to check the progress of evaluation tasks at each stage. Drugs with clear efficacy for survival-threatening diseases will strengthen patient accessibility by imple
- Company
- HPV vaccination for males a necessity rather than an option
- by Whang, byung-woo Mar 14, 2023 05:51am
- Whether the national immunization program (NIP) for the human papillomavirus (HPV) vaccine should be extended to cover males remains a hot issue in Korea. With the NIP applied for its use in girls aged 12 years or older, the government extended the program to include those aged 13 to 17 (born between 2004 to 2008) and low-income women aged 18
- Company
- The erectile dysfunction tx market sales are at an all-time
- by Chon, Seung-Hyun Mar 14, 2023 05:51am
- Hanmi Pharmaceutical PalPal Leads for 7 Consecutive Years. Continuation of Dominant System Last year, the domestic erectile dysfunction treatment market grew to the largest ever. Domestic companies' generic products dominated the market, accounting for nearly 90% of the market. According to IQVIA, a drug research institute on the 8th, the size
- Policy
- SGLT2 + DPP4 combi benefit expansion has increased
- by Lee, Tak-Sun Mar 14, 2023 05:50am
- As the insurance authorities decided to expand the combined coverage of major diabetes drugs from April, applications for reimbursement for related complex drugs are continuing. MSD Stegluzan's application for benefits was recently confirmed, and Dong-A ST Sugadapa, which was approved on the 13th, plans to apply for benefits this month. Accor
- Company
- Will the new prostate cancer drug Erleada be reimb in April?
- by Eo, Yun-Ho Mar 14, 2023 05:50am
- Whether the new prostate cancer drug ‘Erleada’ will be listed for reimbursement is gaining industry attention. The drug pricing negotiation period for Janssen Korea’s metastatic hormone-sensitive prostate cancer (mHSPC) treatment Erleada (apalutamide) with the National Health Insurance Service is about to expire this month (March).
- Policy
- Voluntary withdrawal of reimbursement for Tepmeko
- by Lee, Tak-Sun Mar 14, 2023 05:50am
- It was found that Tepmeko, a MET mutated anti-cancer drug that failed to set reimbursement standards, recently voluntarily withdrew its application for reimbursement. Tepmeko has not been recognized as valid as a result of discussing the reimbursement standard in HIRA. According to the industry on the 10th, Merck announced its intention to vo
- Policy
- Innovative plans for domestic vaccines/txs to face post-pand
- by Lee, Jeong-Hwan Mar 13, 2023 05:53am
- The government will promptly import vaccines and treatments for new infectious diseases that will occur in Korea after Corona 19 and improve laws and systems so that domestic products can be produced quickly. For now, only the big direction has been set, and the government plans to announce a comprehensive plan in May after consultations wit
- Company
- Eylea makes sole lead in the ₩100B nAMD Tx market
- by Jung, Sae-Im Mar 13, 2023 05:53am
- The sole lead held by ‘Eylea’ in the domestic macular degeneration treatment market has been further solidified last year. Also, Novartis has been aggressively promoting sales of its recently launched new drug ‘Beovu.' With Novartis focusing its sales strategy on Beovu, sales of the company’s lesser priority, 'Lucentis,’ further decli
- Company
- Pharmaceutical companies are fiercely competing to develop
- by Kim, Jin-Gu Mar 13, 2023 05:53am
- In the hyperlipidemia combination drug market of 'statin + ezetimibe', competition to develop a two-drug combination using 'low-dose statin' is intensifying. According to the pharmaceutical industry on the 11th, Yuhan Corporation is developing a combination drug for hyperlipidemia with Ezetimibe added to Atorvastatin 5mg through its subsidiar
- Company
- Gastric cancer is the first immuno-oncology option available
- by Eo, Yun-Ho Mar 13, 2023 05:53am
- In the field of gastric cancer, attention is paid to whether the first immuno-oncology drug insurance benefit registration can be achieved. As a result of the coverage, it is possible to propose the HIRA in April for Opdivo, an immune anticancer drug with PD-1 inhibitory mechanism, from Ono Korea Pharmaceuticals and Korea BMS Pharmaceuticals.
